Next Article in Journal
MPL Y252H and MPL F126fs Mutations in Essential Thrombocythemia: Case Series and Review of Literature
Previous Article in Journal
Patterns of Prescribing Hydroxyurea for Sickle Cell Disease Patients from a Central Hospital, Saudi Arabia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 11
Issue 1
10.4081/hr.2019.7800
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant

by
Claire Horgan
,
Alexandros Kanellopoulos
,
Shankara Paneesha
,
Bhuvan Kishore
,
Richard Lovell
and
Emmanouil Nikolousis
*
Hematology and Stem Cell Transplantation Department, Heart of England NHS Trust, Bordesley Green East, Birmingham B9 5SS, UK
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2019, 11(1), 7800; https://doi.org/10.4081/hr.2019.7800
Submission received: 26 July 2018 / Revised: 5 November 2018 / Accepted: 15 November 2018 / Published: 25 February 2019

Abstract

A unique case of primary refractory FLT3-itd mutated acute myeloid leukemia in an elderly patient, who achieved completed morphological remission, and FLT3-itd negativity, following 9 cycles of azacitadine in combination with escalating doses of donor lymphocyte infusions following relapse 18 months post reduced intensity HLAA mismatch Campath conditioning allogeneic stem cell transplant.
Keywords: acute myeloid leukaemia; FLT-3 mutation; azacitidine acute myeloid leukaemia; FLT-3 mutation; azacitidine

Share and Cite

MDPI and ACS Style

Horgan, C.; Kanellopoulos, A.; Paneesha, S.; Kishore, B.; Lovell, R.; Nikolousis, E. A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant. Hematol. Rep. 2019, 11, 7800. https://doi.org/10.4081/hr.2019.7800

AMA Style

Horgan C, Kanellopoulos A, Paneesha S, Kishore B, Lovell R, Nikolousis E. A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant. Hematology Reports. 2019; 11(1):7800. https://doi.org/10.4081/hr.2019.7800

Chicago/Turabian Style

Horgan, Claire, Alexandros Kanellopoulos, Shankara Paneesha, Bhuvan Kishore, Richard Lovell, and Emmanouil Nikolousis. 2019. "A Unique Case of Durable Complete Remission after Salvage with Azacitidine and DLI for High Risk FLT-3 Positive Acute Myeloid Leukemia, Following Relapse 18 Months Post Allogeneic Stem Cell Transplant" Hematology Reports 11, no. 1: 7800. https://doi.org/10.4081/hr.2019.7800

Article Metrics

Back to TopTop